Page 1 of 1

FILING DATE Aggst 28, 2003  APPLICANT Cassart et al.  GROUP  EXAMINER  MID-TEAM Davis  LIS. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  Lisue Date Number  Patent Number  Patent Number  FOREIGN PATENT DOCUMENTS  FOREIGN PATENT DOC	FORM PTO					SERIAL NO.		10/650,6	08	
Examiner Initials    Patent Number   Issue Date   Name   Class   Subclass   Filing Date   If Appropriate	INFORMA	TION	DISCLOSURE ST	ATEMENT				August 2		
Examiner Initials  Patent Number  Patent Number  Poccional Properties  FOREIGN PATENT DOCUMENTS  Filing Date Name  Class Subclass  Filing Date If Appropriate Initials  MIDI 1. 20050260634 11/24/2005 Baldwin et al.  MIDI 2. 6,451,320 9/2002 Stephenne et al.  FOREIGN PATENT DOCUMENTS  Publication  Number  Publication  Number  Country  Class Subclass  Translation  Number  OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  MIDI 3. BOWIE et al., Science 257:1306-1310 (1990).  4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).  5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).  6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).  7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).  8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).  9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).  10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13889 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  2HANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells.								Cassart		
Number						GROUP		1642		
List Patent   Issue Date   Name   Class   Subclass   Mappropriate								Min-Tar	n Davis	
Patent Number   Issue Date   Name   Class   Subclass   Filiag Date   I/Appropriat									)-1US	
Patent   Issue Date   Name   Class   Subclass   If Appropriat				U.S. F	PATENT D	OCUMENTS				
Initials Number Solutions Studies Stud										
MDI   1. 20050260634   11/24/2005   Baldwin et al.			Patent	Issue Date	Name		Class	Subclass	If Appropriate	
Stephenne et al.   FOREIGN PATENT DOCUMENTS		1	Number							
FOREIGN PATENT DOCUMENTS    Document Number   Publication Date   Country   Class   Subclass   Translation Yes   No	וטואו	1.	20050260634	11/24/2005	Baldwin et al.					
FOREIGN PATENT DOCUMENTS    Document Number   Publication Date   Country   Class   Subclass   Translation Yes   No	/MD/	2.	6,451,320	9/2002	Stephenn	e et al.		<u> </u>		
Document Number   Publication   Country   Class   Subclass   Translation   Yes   No		1			1		†			
Document Number   Publication   Date   Country   Class   Subclass   Translation   Yes   No										
Document Number   Publication   Date   Country   Class   Subclass   Translation   Yes   No			<del></del>	FOREIG	N PATEN	T DOCUMENTS	<u> </u>		1	
Number  Date  Country  Class  Subclass  Yes   No  OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)  BOWIE et al., Science 257:1306-1310 (1990).  4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).  5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).  6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).  7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).  8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).  9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).  10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: NAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		T			1	T BOCCHENTS		Translatio		
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)    MD  3. BOWIE et al., Science 257:1306-1310 (1990).   4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).   5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).   6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).   7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).   8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell. An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).   9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).   10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-Al, Int. J. Cancer 80:219-230 (1999).   11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).   12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).   13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).   14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).   15. Protein GenPep Accession Number: NP 005161.1   16. Protein GenPep Accession Number: AAB86993.1		ł				Country	Class	Subclass		
MD  3. BOWIE et al., Science 257:1306-1310 (1990).   4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).   5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).   6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).   7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).   8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).   9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).   10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).   11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).   12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).   13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).   14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).   15. Protein GenPep Accession Number: NP 005161.1   16. Protein GenPep Accession Number: AAB86993.1   2HANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,						<u> </u>	Class	Bubchis	<del></del>	
MDI   3. BOWIE et al., Science 257:1306-1310 (1990).   4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).   5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).   6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).   7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).   8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).   9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).   10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)   11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).   12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).   13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).   14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).   15. Protein GenPep Accession Number: NP 005161.1   16. Protein GenPep Accession Number: AAB86993.1   2HANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,				<del></del>				<del>                                     </del>	<del>-</del>	
MDI   3. BOWIE et al., Science 257:1306-1310 (1990).   4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).   5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).   6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).   7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).   8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).   9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).   10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).   11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).   12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).   13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).   14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).   15. Protein GenPep Accession Number: NP 005161.1   16. Protein GenPep Accession Number: AAB86993.1			<del></del>					<del> </del>		
MD  3. BOWIE et al., Science 257:1306-1310 (1990).   4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).   5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).   6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).   7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).   8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).   9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).   10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).   11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).   12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).   13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).   14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).   15. Protein GenPep Accession Number: NP 005161.1   16. Protein GenPep Accession Number: AAB86993.1   2HANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		1			· · ·		<del></del>	<del>                                     </del>		
MD  3. BOWIE et al., Science 257:1306-1310 (1990).   4. BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).   5. FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).   6. GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).   7. HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).   8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).   9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).   10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).   11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).   12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).   13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).   14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).   15. Protein GenPep Accession Number: NP 005161.1   16. Protein GenPep Accession Number: AAB86993.1   2HANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,	···········	-	OTHER DOCUM	MENTS (Includi	ng Author.	Title, Journal-Da	te Page Nu	nher Etc.)	<b>L</b>	
<ol> <li>BURGESS et al., J. of Cell Bilogy 11:2129-2138 (1990).</li> <li>FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).</li> <li>GILLES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).</li> <li>HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).</li> <li>KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell. An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).</li> <li>LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).</li> <li>MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HI.A-A1, Int. J. Cancer 80:219-230 (1999)</li> <li>OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).</li> <li>ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).</li> <li>TAO et al., The J. of Immunology 143(8):2595-2601 (1989).</li> <li>TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).</li> <li>Protein GenPep Accession Number: NP 005161.1</li> <li>Protein GenPep Accession Number: AAB86993.1</li> <li>ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,</li> </ol>	/MD/	3.					te, rage iva	inder, Etc.)		
<ol> <li>FOWLKES et al., T-Cell Tolerance, Current Opinino in Immunology 5:873-879 (1993).</li> <li>GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).</li> <li>HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).</li> <li>KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).</li> <li>LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).</li> <li>MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).</li> <li>OKA et al., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).</li> <li>ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).</li> <li>TAO et al., The J. of Immunology 143(8):2595-2601 (1989).</li> <li>TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).</li> <li>Protein GenPep Accession Number: NP 005161.1</li> <li>Protein GenPep Accession Number: AAB86993.1</li> <li>ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,</li> </ol>		_								
<ol> <li>GILLIES et al.m, Human Antibodies and Hybrodomas, 1(1):47-54 (1990).</li> <li>HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).</li> <li>KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).</li> <li>LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).</li> <li>MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).</li> <li>OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).</li> <li>ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).</li> <li>TAO et al., The J. of Immunology 143(8):2595-2601 (1989).</li> <li>TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).</li> <li>Protein GenPep Accession Number: NP 005161.1</li> <li>Protein GenPep Accession Number: AAB86993.1</li> <li>ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,</li> </ol>			FOWLKES et al.	T-Cell Tolerand	ce Current	Onining in Immune	logy 5:873-8	79 (1993)		
<ol> <li>HOOS et al., A Clinical Development Paradigm for Cancer Vaccines and Related Biologics, J. Immunotherapy 30(1):1-15 (Jan. 2007).</li> <li>KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell. An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).</li> <li>LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).</li> <li>MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)</li> <li>OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).</li> <li>ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).</li> <li>TAO et al., The J. of Immunology 143(8):2595-2601 (1989).</li> <li>TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).</li> <li>Protein GenPep Accession Number: NP 005161.1</li> <li>Protein GenPep Accession Number: AAB86993.1</li> <li>ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,</li> </ol>			GILLIES et al m	Human Antihod	ies and Hyl	orodomas 1(1):47-	54 (1990)	73 (1993).		
Immunotherapy 30(1):1-15 (Jan. 2007).  8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell. An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).  9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).  10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999).  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,			HOOS et al., A C	linical Developm	rent Paradio	m for Cancer Vac	rines and Rel	ated Biologics	Ţ	
8. KYEWSKI et al., Intrathymic Presentation of Circulating Non-MHC Antigens by medullary Dendritic Cell An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).  9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).  10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,	1	' '	Immunotherapy 3	0(1):1-15 (Jan. 2	2007)	in for Cancer vac	ines and Rei	ated Diologics,	J.	
An antigen-dependent Microenvironment for T Cell Differentiation, J. Exp. Med., 163:231-245 (1986).  9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).  10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		8.	KYFWSKI et al. Intrathymic Presentation of Circulating Non MUC Antigons by moduling No. 124. G. 11.							
<ul> <li>9. LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).</li> <li>10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)</li> <li>11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).</li> <li>12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).</li> <li>13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).</li> <li>14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).</li> <li>15. Protein GenPep Accession Number: NP 005161.1</li> <li>16. Protein GenPep Accession Number: AAB86993.1</li> <li>ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,</li> </ul>	1 1		An antigen-depen	dent Microenviro	onment for	T Cell Differentiat	ion J Exn M	led 163:231-2	45 (1986)	
10. MARCHAND et al., Tumor Regressions Observed in Patients with Metastitic melanoma Treated with an Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		9.	LAZAR et al., Molecular and Cell Biology 8:1247-1252 (1988).							
Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HLA-A1, Int. J. Cancer 80:219-230 (1999)  11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		10.	MARCHAND et al., Tumor Regressions Observed in Patients with Metactitic melanoma Treated with an							
11. OKA et al., Induction of WTI (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,			Antigenic Peptide Encoded by Gene MAGE-3 and Presented by HI.A-A1. Int. J. Cancer 80:219-230 (1990)							
vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).  12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		11.	OKA et al., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTI pentide							
12. ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines, Nat Med 10(9):909-915 (Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,			vaccine and the resultant cancer regression, PNAS 101(38):13885-13890 (Sept. 2004).							
(Sept. 2004).  13. TAO et al., The J. of Immunology 143(8):2595-2601 (1989).  14. TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		12.	ROSENBERG et al., Cancer Immunotherapy: moving beyond current vaccines. Nat Med 10(9):909-915							
<ul> <li>TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Opin. Biol. Ther. 5(6):799-807 (2005).</li> <li>Protein GenPep Accession Number: NP 005161.1</li> <li>Protein GenPep Accession Number: AAB86993.1</li> <li>ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,</li> </ul>	4 6		(Sept. 2004).							
(2005).  15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,		13.	TAO et al., The J. of Immunology 143(8):2595-2601 (1989).							
15. Protein GenPep Accession Number: NP 005161.1  16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,	1 1	14.	TSURUMA et al., Peptide-based vaccination for colorectal cancer, Expert Onin, Biol. Ther. 5(6):799-807							
16. Protein GenPep Accession Number: AAB86993.1  ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,										
ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells,										
ZHANG et al., Induction of Specific T Cell Tolerance by Fas Ligand-Expressing Antigen-Presenting Cells, of Immunology 162:1423-1430 (1999).		16.								
of Immunology 162:1423-1430 (1999).	W		ZHANG et al., In	duction of Specif	fic T Cell T	olerance by Fas Lip	gand-Express	ing Antigen-Pr	esenting Cells, J.	
	<del></del>		of Immunology 1	<b>62:1423-1430 (1</b> 9	999).					
			<del> </del>							
			ļ							
EXAMINER /Minh Tam Davis/ (04/05/2007)  DATE CONSIDERED	XAMINER	<b>L</b>	/Minh Tam Da	vis/ (04/05/200	7)		DATE	CONSIDERE	D	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through	XAMINER	: Initi	al if citation conside	red, whether or r	ot citation	is in conformance	with MPEP 8	609: Draw line	through	
citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	itatian if na	t in co	nformance and not c	onsidered Inchi	de conv of	this form with next	communicat	ion to the anni	cant	